Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
61
resultados
Última actualización
08/08/2025 [07:48:00]
Resultados 25 a 50 de 61
Resumen de: EP4582144A2
The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
Resumen de: WO2025138512A1
Provided are an apolipoprotein E detection reagent and the use thereof. The reagent comprises at least one of an ApoE2 protein detection reagent, an ApoE3 protein detection reagent and an ApoE4 protein detection reagent. One of a capture antibody and a detection antibody used for detecting ApoE2 protein or ApoE4 protein is a specific monoclonal antibody, and the capture antibody and the detection antibody used for detecting ApoE3 are both specific monoclonal antibodies. Genotyping of ApoE and quantitative detection of different genotypes of proteins are performed on the basis of an immunological detection method. The detection method has the advantages of being simple, easy to operate, short in time and cheap. A genotype detection result is highly consistent with a fluorescence PCR result. Genotyping of ApoE (6 types) can be performed, which is used to replace the nucleic acid detection and guide medication, and clarify the correlation of the ApoE4 genotype homozygosity/heterozygosity and the protein concentration of ApoE4 with AD.
Resumen de: US2025215504A1
The present invention includes a method for analyzing tRNAHisGTG fragments. In one aspect, the present invention includes a method of identifying a subject in need of therapeutic intervention to treat and/or prevent a disease or condition, disease recurrence, or disease progression comprises characterizing the identity of tRNAHisGTG fragments. The invention further includes diagnosing, identifying or monitoring a disease or condition, a panel of engineered oligonucleotides, a kit for a high-throughput assay, and a method and system for identifying tRNAHisGTG fragments.
Resumen de: WO2024042210A1
The invention relates to methods and uses of cell free histone H3 isoforms H3.1, H3.2, H3t and/or H3.3 (or cell free nucleosomes containing said isoforms) of determining the origin of a cell free histone or cell free nucleosome in a body fluid sample as originating from a dividing or non-dividing cell.
Resumen de: AU2023329158A1
The invention relates to methods of detecting, diagnosing or monitoring an inflammatory condition of the central nervous system, in particular by detecting or measuring neutrophil extracellular traps, extracellular traps and/or cell free nucleosomes.
Resumen de: CN119744269A
Provided herein are antibodies or fragments thereof that specifically bind to the microtubule binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting MTBR species in blood or cerebrospinal fluid, as well as the use of such detection for diagnosing, prognosing or staging pathological characteristics and/or clinical symptoms of tauopathy, and selecting a treatment suitable for a given disease stage.
Resumen de: EP4578872A1
Provided is an anti-TREM2 single-domain antibody, consisting of heavy chains comprising CDR1 represented by any one of SEQ ID NOs: 34-40, CDR2 represented by any one of SEQ ID NOs: 41-45, and CDR3 represented by any one of SEQ ID NOs: 46-50. The single-domain antibody has good affinity with TREM2.
Resumen de: US2025208135A1
The present invention provides a method for early detection or diagnosis of a neurodegenerative disease, disorder, or condition in a subject at risk of developing or suspected of having the neurodegenerative disease, disorder, or condition, the method comprising measuring in a blood sample obtained from the subject or a fraction thereof the levels of at least one biomarker selected from CD38+ peripheral blood mononuclear cells (PBMCs), trigonelline, GLUT1 expression in CD4+ T cells, Th2, Th2/Th1 ratio, naïve T cells, adenosine, allose, and HLA-DR T cells, as well as related methods and kits.
Resumen de: WO2025137359A1
Among the various aspects of the present disclosure is the provision of assay methods to identify diseases associated with orexin levels. The present teachings include methods to quantify an orexin concentration in a fluid sample, such as a cerebrospinal fluid sample, and identifying and treating diseases, including but not limited to narcolepsy and Alzheimer's disease, from the orexin concentration.
Resumen de: WO2025137077A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.
Resumen de: US2025208143A1
Disclosed are fragments of p53 peptide (P1) and their use in the diagnosis and/or prognosis of Alzheimer's disease (AD) in a biological sample. The invention provides a method based on mass spectrometry analysis for the diagnosis of Alzheimer's disease at the pre-clinical and prodromal stages of the disease and for the prognosis of cognitive decline in a subject, by quantitating the levels of one or more p53 peptide fragments in a biological sample of a subject.
Resumen de: AU2025204068A1
Abstract Provided herein are sulfopropanoic acid derivatives or pharmaceutically acceptable salts thereof, for treating a disease characterized by amyloid and amyloid-like aggregates, e.g., Alzheimer's disease.
Resumen de: WO2025137532A1
Disclosed herein are methods of measuring amyloid β protofibril levels in biological samples. Methods disclosed herein may detect amyloid β protofibril at femtomolar concentrations and selectively measure protofibril as compared to amyloid β monomers.
Resumen de: KR20250094344A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 호르네린(Hornerin) 단백질의 발현 수준이 98배 높게 나타나는 것을 확인함에 따라 호르네린(Hornerin) 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: KR20250094346A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 Rab2A(Ras-related protein Rab-2A) 단백질의 발현 수준이 15배 높게 나타나는 것을 확인함에 따라 Rab2A(Ras-related protein Rab-2A) 단백질 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: KR20250094349A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 TMEM266(Transmembrane protein 266) 단백질의 발현 수준이 11배 높게 나타나는 것을 확인함에 따라 TMEM266(Transmembrane protein 266) 단백질 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: KR20250094345A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 판테테이나제(Pantetheinase) 단백질의 발현 수준이 48배 높게 나타나는 것을 확인함에 따라 판테테이나제(Pantetheinase) 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: KR20250094347A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 BCAM(Basal cell adhesion molecule) 단백질의 발현 수준이 13배 높게 나타나는 것을 확인함에 따라 BCAM(Basal cell adhesion molecule) 단백질 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: KR20250094348A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 갈렉틴-7(Galectin-7) 단백질의 발현 수준이 11배 높게 나타나는 것을 확인함에 따라 갈렉틴-7(Galectin-7) 단백질 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: PH12021552938A1
The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encelopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: AU2023406056A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Resumen de: WO2024052650A1
The invention relates to neurodegenerative disorders, and the diagnosis and/or prognosis of neurodegenerative disorders in a test subject using a lateral flow test, or the like. The invention also relates to detecting diagnostic and prognostic biomarkers in a range of various patient sample types for diagnosing and/or prognosing neurodegenerative disorders, such as Alzheimer's disease. The invention further provides biomarker detection methods, and apparatus and apparatuses for diagnosing and prognosing neurodegenerative disorders, and methods of treating patients diagnosed or prognosed with a neurodegenerative disorder. The invention also extends to detection of biomarkers and/or screening in pre-symptomatic subjects, for early diagnosis, to enable disease prevention or intervention.
Resumen de: WO2025123398A1
An Alzheimer's disease biomarker based on a brain metabolite and a use thereof. The biomarker comprises any one or a combination of at least two of palmitic acid, DHA, gallic acid, 11Z,14Z,17Z-eicosatrienoic acid, glycodeoxycholic acid, palmitoleic acid, linoleic acid, erucic acid, petroselinic acid, and arachidonic acid. The level of a metabolite is detected to assist in early diagnosis of the Alzheimer's disease, thus facilitating rapid detection; in addition, the present invention has the characteristics of timeliness, convenience, high specificity and high sensitivity.
Resumen de: WO2025125705A1
An in vitro procedure for diagnosing or determining the risk of a person developing Alzheimer's disease (AD), said procedure detecting and quantifying the expression products of the LMNA gene (SEQ. ID: No. 3): lamin A protein (SEQ. ID: No. 1) and its precursor prelamin A (SEQ. ID: No. 2), in a sample of peripheral nerve or smooth muscle.
Nº publicación: WO2025128726A1 19/06/2025
Solicitante:
UNIV NORTHWESTERN [US]
NORTHWESTERN UNIVERSITY
Resumen de: WO2025128726A1
Disclosed herein are methods for analyzing oligomeric protein structures by mass spectrometry. The method includes providing a sample having one or more oligomers; producing, with an ion source, ions of the sample, each of the ions having a mass-to-charge (m z) ratio; detecting a multiplicity of ions generated with a current detector; determining ion masses for each of the multiplicity of ions detected with the current detector with a mass analyzer; generating a mass-domain spectrum from the ion masses with the mass-analyzer, the mass-domain spectrum having one or more mass-domain peaks; and determining one or more metrics capturing the mass heterogeneity and/or mass abundance of oligomers. Methods for diagnosing a subject, assessing treatment efficacy, and assessing treatment efficacy are also provided.
BOPI
Sede Electrónica
